EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Xiebai San Alleviates Allergic Pulmonary Inflammation by Modulating Arachidonic Acid Metabolism

Xingnan Yue, Jiayin Han, Chen Pan, Yushi Zhang iD, Suyan Liu, Feng Gao, Yong Zhao, Jingwen Wu, Yuhao Wang, Xi Cheng, Aihua Liang

Pharmaceuticals · 09.03.2026 · 19 (3) · 440

DOI: 10.3390/ph19030440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 09.03.2026. Verfasst von Xingnan Yue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CACMS Innovation Fund, State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, NSFC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xiebai San (XBS), a classical Traditional Chinese Medicine formula comprising Cortex mori, Lycii Radicis Cortex, and Glycyrrhizae Radix et Rhizoma, has long been used for pulmonary inflammatory disorders. However, its underlying mechanisms remain un-clear. This study aimed to investigate the mechanisms by which XBS alleviates allergic pulmonary inflammation.

Methods

Two murine models were established, consisting of a chronic ovalbumin (OVA)-induced model simulating adaptive immune responses and an acute compound 48/80-induced model triggering non-IgE-dependent mast cell activation. Pharmacodynamic indices including serum IgE, histamine, inflammatory cytokines, leukocyte profiles, and lung histopathology were evaluated. Network pharmacology was employed to predict core pathways. Arachidonic acid metabolites (AAMs) in lung tissues were quantified by targeted UPLC-MS/MS, and p38 MAPK signaling proteins were assessed by Western blot.

Results

XBS significantly alleviated lung injury in both models. In the chronic OVA-induced model, XBS significantly reduced serum immunoglobulin E levels and inflammatory cell infiltration. In the acute model, XBS suppressed histamine release and mast cell-mediated inflammatory responses. Targeted metabolomics revealed differential regulatory mechanisms: XBS reduced lipoxygenase-derived metabolites, including leukotrienes and 12-hydroxyeicosatetraenoic acid in chronic inflammation, while suppressing cyclooxygenase-related prostaglandins in acute inflammation. Network pharmacology analysis identified arachidonic acid (AA) metabolism as a potential central pathway. The p38 mitogen-activated protein kinase pathway was partially involved.

Conclusions

XBS effectively alleviates both chronic and acute allergic pulmonary inflammation through differential modulation of AA metabolism, providing mechanistic insights supporting its traditional use in allergic airway diseases.

Schlagwörter

Stichwörter der Autor:innen

Xiebai Sanacute allergic pulmonary inflammationarachidonic acidchronic allergic pulmonary inflammationp38 MAPK pathway

Autor:innen und Institutionen

  • Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.

ORCID-Profile: Yushi Zhang

Förderung

  • CACMS Innovation Fund
  • State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs
  • NSFC
  • Fundamental Research Funds for the Central public welfare research institutes
  • Scientific and technological innovation project of China Academy of Chinese Medical Sciences
  • CACMS Foundation

Zitieren

APA

Yue, X., Han, J., Pan, C., Zhang, Y., Liu, S., Gao, F., Zhao, Y., Wu, J., Wang, Y., Cheng, X., & Liang, A. (2026). Xiebai San Alleviates Allergic Pulmonary Inflammation by Modulating Arachidonic Acid Metabolism. Pharmaceuticals, 19(3), 440. https://doi.org/10.3390/ph19030440

Vancouver

Yue X, Han J, Pan C, Zhang Y, Liu S, Gao F, et al. Xiebai San Alleviates Allergic Pulmonary Inflammation by Modulating Arachidonic Acid Metabolism. Pharmaceuticals. 2026;19(3):440. doi:10.3390/ph19030440

BibTeX
@article{Yue2026,
  author = {Yue, Xingnan and Han, Jiayin and Pan, Chen and Zhang, Yushi and Liu, Suyan and Gao, Feng and Zhao, Yong and Wu, Jingwen and Wang, Yuhao and Cheng, Xi and Liang, Aihua},
  title = {Xiebai San Alleviates Allergic Pulmonary Inflammation by Modulating Arachidonic Acid Metabolism},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {3},
  pages = {440},
  doi = {10.3390/ph19030440}
}
Kostenlos starten →